


LISTING OF THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application.

Claim 1 (canceled)

Claim 2 (previously presented): The method of claim 6, wherein the macrolide compound is a tricyclo compound (I) of the following formula



wherein

adjacent pairs of R¹ and R², R³ and R⁴, and R⁵ and R⁶ each independently

a) consist of two adjacent hydrogen atoms, wherein R² is optionally alkyl, or

b) form another bond between carbon atoms binding with the members of each pair;

R^7 is hydrogen atom, hydroxy, alkyloxy or protected hydroxy, or may form oxo with R^1 ;

R^8 and R^9 each independently are hydrogen atom or hydroxy;

R^{10} is hydrogen atom, alkyl, alkenyl, alkyl substituted by one or more hydroxy, alkenyl substituted by one or more hydroxy, or alkyl substituted by oxo;

X is oxo, (hydrogen atom, hydroxy), (hydrogen atom, hydrogen atom), or a group of the formula $-\text{CH}_2\text{O}-$;

Y is oxo, (hydrogen atom, hydroxy), (hydrogen atom, hydrogen atom), or a group of the formula $\text{N}-\text{NR}^{11}\text{R}^{12}$ or $\text{N}-\text{OR}^{13}$;

R^{11} and R^{12} each independently are hydrogen atom, alkyl, aryl or tosyl;

R^{13} , R^{14} , R^{15} , R^{16} , R^{17} , R^{18} , R^{19} , R^{22} and R^{23} each independently are hydrogen atom or alkyl;

R^{24} is an optionally substituted ring which optionally contains one or more hetero atom(s); and

n is 1 or 2,

wherein

Y, R^{10} and R^{23} optionally form, together with the carbon atom they bind with, a saturated or unsaturated 5 or 6-membered heterocyclic group containing nitrogen atom, sulfur atom and/or oxygen atom, wherein the heterocyclic group may be substituted by one or more group(s) selected from the group consisting of alkyl, hydroxy, alkyloxy, benzyl, a group of the formula $-\text{CH}_2\text{Se}(\text{C}_6\text{H}_5)$, and alkyl substituted by one or more hydroxy,

U.S. Application No.: 09/926,411
Reply to Office Action dated August 7, 2003

or a pharmaceutically acceptable salt thereof.

Claim 3 (previously presented): The method of claim 6 or claim 2, wherein said macrolide compound is FK506.

Claim 4 (currently amended): The method of claim 6, wherein said macrolide compound is administered in the form of a preparation suitable for ~~local administration to the eye as an eye drop.~~

Claim 5 (canceled)

Claim 6 (currently amended): A method for treating a dry eye, comprising administering ocular administration of an effective amount of a macrolide compound to a subject in need of the treatment of dry eye.

Claim 7 (canceled)

Claim 8 (previously presented): The method of claim 6, wherein said macrolide compound is administered in the form of a preparation suitable for local administration.

U.S. Application No.: 09/926,411
Reply to Office Action dated August 7, 2003

Claim 9 (previously presented): The method of claim 6, wherein said macrolide compound is administered in an amount of 0.0001 to 1000 mg.

Claim 10 (previously presented): The method of claim 9, wherein said macrolide compound is FK506.

Claim 11 (previously presented): The method of claim 6, wherein said macrolide compound is administered in an amount of 0.001 to 500 mg.

Claim 12 (previously presented): The method of claim 11, wherein said macrolide compound is FK506.

Claims 13-24 (canceled)